Señales en vivo de MXCT | Maximiza tus Ganancias con Getagraph.com

COMPRAR 136836 min ago

@ $4.78

Emitido: 14 feb 2024 @ 12:00

Retorno: -2.30%

Señal anterior: feb 13 - 10:49

Señal anterior: Vender

Retorno: -0.46 %

Live Chart Being Loaded With Signals

Commentary (17 may 2024 @ 16:00):

Stats
Volumen de hoy	270 413
Volumen promedio	560 692
Capitalización de mercado	488.22M
EPS	$0 ( 2024-05-08 )
Próxima fecha de ganancias	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.34
ATR14	$0.00800 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Johnston John Joseph	Buy	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	100 000	Employee Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	25 000	Common Stock

INSIDER POWER
40.30
Last 100 transactions
Buy: 1 609 082 \| Sell: 743 053

Volumen Correlación

Largo: -0.32 (neutral)

Corto: -0.57 (weak negative)

Signal:(26.684) Neutral

MaxCyte, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MaxCyte, Inc. Correlación - Moneda/Commodity

-0.15
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.30
( neutral )

MaxCyte, Inc. Finanzas

Annual	2023
Ingresos:	$41.29M
Beneficio Bruto:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2023
Ingresos:	$41.29M
Beneficio Bruto:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2022
Ingresos:	$44.26M
Beneficio Bruto:	$39.16M (88.48 %)
EPS:	$-0.190

FY	2021
Ingresos:	$33.89M
Beneficio Bruto:	$30.25M (89.24 %)
EPS:	$-0.210

Financial Reports:

No articles found.

MaxCyte, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.